Our Drugs

In a sector with a great growth potential such as the sector of the pharmaceutical industry, SIPHAT maintains its position of leader of the Tunisian industrial network and is its main component. The stability of its position is the fruit of a strategy based mainly on the variety of its production range: 141 officinal products, 109 hospital products and 135 patent medicines grouped in about fifteen therapeutic classes ensuring quality assurance.

Production capacity

Production sites Production capacity in millions of units
Dry forms 500 (tablets)
10 (capsules)
3 (Sachets)
Pasty forms 4.5 (Tubes)
56 (suppositories)
Liquid forms 25 (drinkable phials)
6 (perfusable bags)
5.6 (syrup flasks)
2.5 (litters of concentrated solutions for haemodialysis)
1.5 perfusable solution bottles
3 injectables ampoules

 

OUR NEW PRODUCTS

Name           DCI                    
Anaspasme Phloroglucinol
Metrogyl Metromidazol
Fenothyl Fenofibrate
Ramitec Ramipril
Prazor Lansoprazole

                                                                                                  

 
  • images/slideshow/01_anaspasm oro.jpg
  • images/slideshow/0_fenothyl.jpg
  • images/slideshow/1.jpg
  • images/slideshow/10_parazor 15mg 283 x 200.jpg
  • images/slideshow/1_parazor 30mg412 x 291.jpg
  • images/slideshow/4.jpg
  • images/slideshow/5.jpg

HEADQUARTERS SIPHAT

Fondouk Choucha
2013 Ben Arous
Tel (+216) 71 381 222
Fax (+216) 71 382 768
siphat@rns.tn
CARDIOLOGIE AND ANGIOLOGIE